Bernard-Soulier Syndrome (BSS) - Treatment

Background

Treatment Overview

• Active bleeding episodes
• Pre-procedural/surgical prophylaxis
• Delivery in pregnant women (with significant bleeding history)

1. Platelet Transfusion (Mainstay of Treatment)

• HLA-matched, single-donor platelets are the primary treatment for significant bleeding.
• Matching is important because repeated transfusions lead to alloimmunization against platelet-specific antigens and HLA antigens, causing transfusion refractoriness.
• Limiting unnecessary transfusions is therefore critical - they should be reserved for active bleeding or high-risk procedures.
• In the obstetric setting, routine prophylactic platelet transfusion before delivery is controversial due to the risk of alloimmune thrombocytopenia (AIT) - reserved only for those with severe bleeding history.

2. Recombinant Factor VIIa (rFVIIa / Eptacog alfa)

• rFVIIa is FDA approved for use in both Glanzmann thrombasthenia and Bernard-Soulier syndrome.
• Indicated especially when patients are alloimmunized and refractory to platelet transfusion.
• Mechanism: enhances thrombin generation at the site of vascular injury, thereby boosting platelet recruitment independently of the GPIb-IX-V complex.
• A 2026 case report (Okamoto et al., Ann Hematol) described successful hemostasis with rFVIIa in a BSS patient refractory to HLA-matched platelets following trauma, with no thromboembolic complications. [PMID: 41746364]
• Dosing: typically follows the regimen used in Glanzmann thrombasthenia surgical settings.

3. DDAVP (Desmopressin)

• Useful for mild to moderate bleeding in BSS, particularly as an adjunct.
• Mechanism: raises plasma vWF and factor VIII levels; may also have direct platelet effects.
• Administered IV at 0.3 mcg/kg.
• Caution: can cause fluid retention and hyponatremia - monitor electrolytes.
• Not sufficient as monotherapy for severe bleeding.

4. Antifibrinolytic Therapy

• Used alone or in combination with DDAVP or platelet transfusion.
• Particularly valuable in tissues of high fibrinolytic activity (nose, mouth, throat, extraocular tissue).

5. Oral Contraceptives

• Used in women with heavy menstrual bleeding (menorrhagia) as supplementary treatment.
• Reduces menstrual blood loss by suppressing endometrial proliferation.

6. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

• Reserved for severe, refractory cases unresponsive to other therapies.
• The only potential curative option currently available.
• Risk-benefit must be carefully considered given transplant-related morbidity.

Special Situations

Obstetric / Peripartum Management

• Postpartum hemorrhage occurs in ~60% of BSS pregnancies; ~50% require blood transfusion (Creasy & Resnik's Maternal-Fetal Medicine).
• HLA-matched platelets preferred to reduce AIT risk.
• Cesarean delivery should be reserved for obstetric indications only.
• Neuraxial anesthesia should be avoided - normal hemostasis is not guaranteed even after prophylactic platelet transfusion.
• DDAVP, tranexamic acid, and rFVIIa are adjuncts for peripartum bleeding control.

Avoid Antiplatelet Drugs

• NSAIDs, aspirin, and other antiplatelet agents must be strictly avoided as they worsen platelet dysfunction.

Treatment Summary Table

Recent evidence note: A 2025 comprehensive review (Kaya, Semin Thromb Hemost 2025, PMID 39191409) confirmed platelet transfusion remains the cornerstone, with rFVIIa recommended in alloimmunized patients and HSCT for refractory cases - consistent with current textbook recommendations. A 2026 case report further supports rFVIIa as an effective rescue option in transfusion-refractory BSS.

Premature Greying of Hair (Canities Praecox)

Definition

Pathophysiology

1. Depletion of melanocyte stem cells in the hair follicle bulge region - reduced migration replenishes fewer active melanocytes each hair cycle.
2. Loss of tyrosinase activity within bulbar melanocytes - this enzyme is rate-limiting for melanin synthesis.
3. Reactive oxygen species (ROS) / H₂O₂ accumulation - oxidative damage to melanocyte DNA (nuclear and mitochondrial) is a key mechanism. Catalase activity declines with age; accumulated H₂O₂ bleaches hair from within and impairs methionine sulfoxide repair.
4. Reduction in melanosomes - fewer and smaller melanosomes transferred to cortical keratinocytes.

Causes

A. Genetic / Hereditary

• Familial (autosomal dominant) - the most common cause; positive family history is the strongest predictor.
• Accounts for early greying that is otherwise unexplained.
• IRF4, MCIR, and other pigmentation gene variants influence onset.

B. Nutritional Deficiencies

C. Endocrine / Autoimmune Disorders

• Vitiligo - most common acquired cause; anti-melanocyte autoimmunity destroys follicular melanocytes (can occur without visible skin lesions)
• Thyroid disorders (hypo- and hyperthyroidism)
• Alopecia areata - "canities subita" (sudden whitening) occurs when all pigmented hairs fall out, leaving only white ones
• Pernicious anaemia (B12 deficiency via intrinsic factor loss)

D. Environmental / Lifestyle

• Smoking - well-established independent risk factor (oxidative stress)
• Chronic psychological stress - activates sympathetic nervous system, depletes melanocyte stem cell pool (documented in animal models and human studies)
• Radiation exposure
• Oxidative stress from UV, pollution, or nutritional antioxidant deficiency

E. Drugs / Medications

F. Syndromes / Genetic Disorders

Treatment

1. Treat Reversible Underlying Causes (Most Important)

• Iron supplementation: reverses canities segmentata sideropenica completely.
• Vitamin B12 replacement: IV or IM cyanocobalamin/methylcobalamin; repigmentation possible if melanocytes intact.
• Thyroid disease management: correct hypothyroidism or hyperthyroidism.
• Copper supplementation: for documented deficiency.
• Vitamin D correction
• Stop offending drugs (chloroquine, TKIs) if clinically feasible.

2. Antioxidant Therapy

• Catalase-based topicals (PC-KUS/Suncat) - a pseudocatalase cream used with narrow-band UVB showed repigmentation in some vitiligo-associated greying cases.
• Oral antioxidants: vitamin E, vitamin C, selenium (supportive evidence only).
• Para-aminobenzoic acid (PABA) - historically used; some early evidence of partial repigmentation.

3. Phototherapy

• Narrow-band UVB (NB-UVB) - used for vitiligo-associated poliosis/greying; stimulates residual melanocytes.
• PUVA - less commonly used now due to side effects.

4. Topical Agents

• Minoxidil - indirectly darkens hair by converting vellus to terminal hairs.
• Topical prostaglandin analogues (latanoprost) - may pigment eyelashes.

5. Emerging / Investigational

• JAK inhibitors (e.g., ruxolitinib, baricitinib) - approved for alopecia areata; some repigmentation of greying hairs observed in alopecia areata patients as a secondary finding.
• Stem cell-based therapies targeting melanocyte stem cell niches are under research.
• Stress reduction and lifestyle modification (smoking cessation, balanced diet, antioxidant-rich foods) - may slow progression.

6. Cosmetic (Non-Medical)

• Hair dyes remain the most effective and widely used option for cosmetic management.
• Henna, semipermanent, and permanent dyes - patient preference guides selection.

Key Takeaway Summary

A 2025 comprehensive review (Desai et al., Int J Dermatol 2025, PMID 39697103) confirmed genetics, oxidative stress, smoking, diet, and associated medical conditions as the main drivers, and highlighted that treatment remains limited - with the greatest benefit from identifying and correcting reversible causes.

Werner Syndrome (Adult Progeria)

Overview

Epidemiology

• Incidence: 1 in 1 million births worldwide.
• Much higher in Japan (1 in 3500 in some communities) due to consanguinity - most reported cases are Japanese.
• Affects both sexes equally.
• Over 800 patients reported worldwide.

Genetics and Pathogenesis

• Caused by loss-of-function mutations in the WRN gene (RECQL2), located on chromosome 8p12.
• The WRN protein is a member of the RecQ helicase family and also has 3'→5' exonuclease activity.
• Functions of WRN protein:
  • Optimizes DNA repair (especially base excision repair)
  • Suppresses illegitimate recombination
  • Maintains telomere integrity
  • Regulates DNA replication fidelity
• Consequence of loss: Genomic instability accumulates, cells undergo premature senescence with reduced replicative capacity, leading to accelerated aging and malignant transformation.
• Over half of Japanese patients are homozygous for a specific splice-site mutation.

• 70 distinct pathogenic variants have been identified across the WRN locus.

• Atypical WS: A subset with identical phenotype carry heterozygous missense mutations in LMNA (lamin A/C gene) instead of WRN - these tend to have earlier onset and more severe manifestations, overlapping with Hutchinson-Gilford Progeria Syndrome (HGPS).

Clinical Features

Cutaneous (Skin/Hair) Features

• Premature greying and thinning of scalp hair (often beginning in childhood, characteristically in late adolescence/early 20s)
• Premature balding
• Scleroderma-like skin - tightening, atrophy, and induration of skin (most prominent on face, forearms, hands, legs, feet)
• Poikiloderma - mottled hyperpigmentation and hypopigmentation
• Loss of subcutaneous fat (lipodystrophy) and muscle wasting, especially in limbs
• Dystrophic, hypoplastic, or absent nails
• Plantar hyperkeratosis and thick keratoses over pressure points (fingers, toes, ankles, elbows, ears)
• Chronic, painful leg ulcers - particularly around malleoli, Achilles tendon, heels, toes; prone to infection due to ischaemia; resistant to treatment
• Dystrophic soft tissue calcifications

Facial Features ("Bird-like Facies")

• Short stature (average height ~1.5 m / 5 ft), spindly limbs, central obesity ("trunk-stocky, extremities-thin" body habitus)
• Small hands and feet
• Thin, pinched face with prominent, proptotic eyes
• Beaked nose, taut lips, circumoral radial furrows
• Protuberant teeth, micrognathia
• High-pitched, hoarse/raspy voice (laryngeal atrophy/vocal cord thickening)

Ocular

• Bilateral posterior subcapsular cataracts - develop in the late 20s to 30s; ophthalmologists are often the first to suspect the diagnosis.

Metabolic / Internal Organ Features

Malignancy Risk

• Normal aging shows a 10:1 epithelial:mesenchymal cancer ratio; WS shifts this to 1:1
• Especially increased in Japanese patients:
  • 50-fold increase in melanoma (mostly acral-lentiginous or mucosal - not UV-related)
  • Thyroid follicular carcinoma (at younger age than general population)
  • Meningioma
  • Soft tissue sarcomas, osteosarcoma, fibrosarcoma
  • Hepatoma
  • Leukemia
  • Breast carcinoma

Prognosis

• Average lifespan: ~54 years (some patients die before age 50)
• Principal causes of death: cardiovascular/cerebrovascular disease and malignancy
• Heterozygous carriers may have elevated rates of malignancy and myocardial infarction compared to the general population.

Pathology / Histology

• Epidermis: hyperkeratosis, atrophy, focal basal layer hyperpigmentation
• Dermis: fibrosis and variable hyalinisation; collagen fibres parallel to epidermis (resembling scar/tendon)
• Appendages (hair follicles, sebaceous glands, eccrine glands): decreased in number, atrophic
• Subcutaneous fat: atrophic, often replaced by hyalinised connective tissue
• Blood vessels: changes typical of diabetic angiopathy

Diagnosis

1. Premature greying/canities
2. Bird-like facies (beaked nose, micrognathia)
3. Short stature
4. Bilateral cataracts

• Genetic testing for WRN mutations (recommended when clinical features are inconclusive)
• Laboratory evaluation for diabetes, hyperlipidaemia, thyroid function
• Detailed diagnostic criteria available at the International Werner Syndrome Registry

Treatment

1. Leg Ulcers (Major Source of Morbidity)

• Treat aggressively and early - debridement, wound care, infection control.
• Skin grafting may be required for resistant ulcers.
• Severe, recalcitrant disease may lead to lower limb amputation.
• Etidronate (bisphosphonate): case reports suggest it can ameliorate painful soft tissue calcifications.

2. Diabetes Mellitus

• Dietary management + appropriate medications:
  • Thiazolidinediones (improve insulin sensitivity)
  • Metformin
  • DPP-4 inhibitors ("gliptins")
• Control reduces atherosclerosis complications.

3. Hyperlipidaemia

• Lipid-lowering agents (statins) to reduce cardiovascular risk.

4. Cataracts

• Surgical cataract extraction - usually successful; ophthalmologists often first to diagnose WS.

5. Osteoporosis

• Calcium, vitamin D, bisphosphonates as appropriate.

6. Cancer Surveillance

• Regular screening for thyroid cancer, melanoma (especially acral/mucosal), soft tissue sarcomas.
• Dermatological surveillance is important.

7. Genetic Counselling

• Offered to all affected families; prenatal diagnosis is possible when the familial mutation is known.

8. Experimental / Emerging Therapies (Under Investigation)

• Vitamin C supplementation: reversed age-related metabolic abnormalities and increased lifespan in a mouse WS model - may be beneficial in humans.
• mTOR inhibitors (rapamycin analogues): under investigation for reducing cellular senescence.
• CRISPR/Cas9-mediated gene correction: experimental; potential future therapeutic direction.

Quick Summary